Skip to main content
. 2016 Jan 29;11(1):e0147330. doi: 10.1371/journal.pone.0147330

Table 7. Results for the Meta-analysis of All Studies of All Athletes and Controls (GENATHLETE, Japan, Australia, Poland, Russia, Spain, Kenya, and Ethiopia); Results in bold type are for p ≤ 0.05.

SNP Chr MAP Gene* Effect Allele N OR P Q I2
rs10874242 1 81,426,166 LPHN2 (153 kb) T 8 1.01 0.94 0.02 57.9
rs17459307 1 162,245,878 NOS1AP A 6 0.80 0.29 0.03 60.8
rs12047209 1 243,791,105 AKT3 C 8 1.09 0.49 0.01 60.5
rs921665 2 3,170,550 TSSC1 (18 kb) A 8 1.07 0.57 0.00 67.2
rs2694093 2 3,254,403 TSSC1 G 8 0.85 0.04 0.07 47.4
rs6548153 2 3,322,274 TSSC1 A 3 1.08 0.68 0.06 63.7
rs6726044 2 68,911,860 BMP10 (40 kb) A 5 1.17 0.41 0.00 84.5
rs2118908 2 111,067,015 ACOXL G 8 1.16 0.20 0.14 36.3
rs2361506 2 233,830,694 MROH2A T 5 0.97 0.76 0.09 50.3
rs7650685 3 11,660,982 VGLL4 G 8 1.01 0.78 0.66 0.0
rs6799372 3 74,481,495 CNTN3 A 7 0.95 0.66 0.00 70.1
rs10938202 4 42,650,320 ATP8A1 C 8 1.06 0.78 0.00 70.4
rs10007111 4 87,828,549 MEPE A 8 1.02 0.76 0.13 37.3
rs4699824 4 100,801,328 EMCN (283 kb), PPP3CA (222 kb) G 8 1.08 0.35 0.02 59.0
rs558129 4 171,829,960 GALNTL6 T 8 0.81 0.0002 0.66 0.0
rs2910756 5 37,859,972 GDNF-AS1 G 8 0.89 0.23 0.02 58.8
rs10499127 6 124,594,509 NKAIN2 G 8 1.10 0.48 0.01 63.4
rs9355947 6 161,887,402 PARK2 A 8 0.94 0.22 0.58 0.0
rs6959675 7 90,253,815 CFAP69 T 3 0.78 0.49 0.32 11.9
rs11975386 7 94,075,721 BET1 (70 kb) A 8 1.15 0.12 0.61 0.0
rs17055965 8 26,769,562 ADRA1A G 7 1.43 0.008 0.21 28.0
rs16906888 8 137,231,375 FAM135B (898 kb) G 6 1.06 0.39 0.46 0.0
rs7861665 9 4,302,988 LOC101929330, GLIS3 (3 kb) T 8 0.84 0.22 0.01 62.4
rs3780169 9 36,979,398 PAX5 T 8 1.02 0.81 0.22 26.4
rs17054974 9 89,549,371 SEMA4D (51 kb), GADD45G (55 kb) C 5 1.32 0.13 0.11 47.4
rs17690338 10 75,357,798 ZNF503-AS1 A 8 0.94 0.24 0.36 9.3
rs2761291 10 93,328,423 MYOF C 3 0.90 0.32 0.44 0.0
rs12573965 11 2,660,402 KCNQ1 C 7 0.87 0.52 0.00 69.9
rs7947391 11 66,419,411 NPAS4 A 8 1.11 0.46 0.00 85.2
rs11613185 12 12,075,733 BCL2L14 A 2 0.91 0.62 0.19 41.5
rs12821816 12 94,976,701 NDUFA12 G 3 0.88 0.44 0.00 82.0
rs61940911 12 110,029,339 ANKRD13A T 6 1.45 0.01 0.29 19.5
rs73195844 12 110,906,768 CCDC63, MYL2 (4 kb) T 5 1.29 0.33 0.01 70.5
rs9580890 13 24,165,281 SPATA13 G 3 0.87 0.35 0.76 0.0
rs9543114 13 72,767,956 DIS3 C 6 1.32 0.26 0.09 48.1
rs9301108 13 106,143,743 DAOA (653 kb), EFNB2 (346 kb) C 7 1.14 0.55 0.00 74.3
rs214003 14 78,336,687 NRXN3 G 8 0.98 0.89 0.01 63.7
rs4776471 15 69,700,119 RPLP1 (245 kb), TLE3 (348 kb) T 8 1.18 0.04 0.01 59.9
rs11856981 15 69,743,207 RPLP1 (288 kb), TLE3 (305 kb) T 8 1.17 0.02 0.09 42.9
rs4288991 16 52,639,252 TOX3 (91 kb) | CHD9 (416 kb) C 8 0.84 0.007 0.31 14.9
rs4541108 17 79,332,527 RBFOX3 A 3 1.05 0.73 0.99 0.0
rs8065364 17 80,189,160 CARD14 C 8 0.95 0.53 0.03 53.8
rs578211 18 49,868,025 MYO5B A 7 1.00 1.00 0.00 74.2
rs4808571 19 17,115,419 MYO9B A 8 1.14 0.30 0.03 56.1
rs62135557 19 19,355,484 MAU2 G 4 1.18 0.59 0.01 76.3

N = Number of studies used in meta-analysis.

OR = odds ratio from a random-effects meta-analysis.

P = p-value for OR from a random-effects meta-analysis.

Q = p-value for Cochrane's Q statistic (tests heterogeneity in effects across individual studies).

I2 (I-squared) = heterogeneity index (0–100; 0 = no heterogeneity, 100 = max. heterogeneity).

MAP based on GRCh38 (hg38).

*The gene located nearest to the SNP. Distance to the gene in kilo bases (1,000 bp) is shown in parentheses. If no distance is shown, the SNP is located within the gene locus.